Abstract: An implantable system for the defibrillation of the atria of a patient's heart includes a pair of atrial defibrillation electrodes configured for delivering a first atrial defibrillation pulse in the heart, and a pulse generator operatively associated with the first pair of atrial defibrillation electrodes for delivering the first atrial defibrillation pulse. The pulse generator delivers a second second atrial defibrillation pulse after the first defibrillation pulse without intervening monitoring thereof to reduce the voltage necessary for the shock, and the pain associated therewith.

Abstract: Novel compounds of formula (1) together with their salts and solvates have a number of uses in medicine, in particular as central muscle relaxants.

Abstract: An implantable system for the defibrillation of the atria of a patient's heart includes a first pair of atrial defibrillation electrodes configured for delivering a first atrial defibrillation pulse along a first current pathway in the heart, and a pulse generator operatively associated with the first pair of atrial defibrillation electrodes for delivering the first atrial defibrillation pulse. A second pair of atrial defibrillation electrodes configured for delivering a second atrial defibrillation pulse along a second current pathway in the heart is also included, with the second current pathway being different from the first current pathway. A pulse generator is operatively associated with the second pair of atrial defibrillation electrodes for delivering the second atrial defibrillation pulse after the first defibrillation pulse.

Abstract: An implantable system for the defibrillation of the atria of a patient's heart includes a pair of atrial defibrillation electrodes configured for delivering a first atrial defibrillation pulse in the heart, and a pulse generator operatively associated with the first pair of atrial defibrillation electrodes for delivering the first atrial defibrillation pulse. The pulse generator delivers a second second atrial defibrillation pulse after the first defibrillation pulse without intervening monitoring thereof to reduce the voltage necessary for the shock, and the pain associated therewith.

Abstract: Novel compounds of formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each selected from hydrogen and fluoro and at least one and not more than two is fluoro;R.sup.5 is selected from hydrogen and C.sub.1 -C.sub.4 alkyl;R.sup.6 is selected from hydrogen, C.sub.1 -C.sub.4 ally and hydroxy; orR.sup.5 and R.sup.6 together with the ring carbon form a carbonyl group;R.sup.7 is selected from hydrogen and hydroxy,R.sup.8 and R.sup.9 are each selected from hydrogen, C.sub.1 -C.sub.4 alkyl and cyclo(C.sub.3 or C.sub.4) alkyl or together with the nitrogen form a morpholino group; andX is selected from a bond, methylene and --O-- and is always a bond or --O-- when any of R.sup.5, R.sup.6 and R.sup.7 is other than hydrogen and is always a bond when R.sup.5 and R.sup.6 together with the ring carbon form a carbonyl group;and their salts and solvates have a number of uses as central muscle relaxants. In particular, treatment of conditions associated with abnormally raised skeletal muscle tone.

Abstract: The invention provides as new compounds cis-xis-cis-tetrasubstituted cyclopentane compounds which are expected to be useful as chelating agents for alkaline earths, transition, lanthanide, and actinide metal ions. The compounds have Formula (I). Each of the groups X.sup.1, X.sup.2, X.sup.3, and X.sup.4 comprises at least one potential ligand donor group, or one of the groups X or Z may comprise a group which may permit attachment to a biological active molecule or insoluble support.